Published in J Clin Oncol on May 10, 2005
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol (2009) 2.48
Endothelial podosome rosettes regulate vascular branching in tumour angiogenesis. Nat Cell Biol (2014) 2.22
An oligonucleotide microarray for high-throughput sequencing of the mitochondrial genome. J Mol Diagn (2006) 1.40
Bombesin induces angiogenesis and neuroblastoma growth. Cancer Lett (2007) 1.28
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer (2009) 1.24
Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J Thorac Oncol (2009) 1.10
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097). J Thorac Oncol (2010) 1.07
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Target Oncol (2009) 1.07
Estradiol and nicotine exposure enhances A549 bronchioloalveolar carcinoma xenograft growth in mice through the stimulation of angiogenesis. Int J Oncol (2006) 1.05
Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Oncologist (2010) 1.04
VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib. Br J Cancer (2012) 0.95
Aryl hydrocarbon receptor-induced adrenomedullin mediates cigarette smoke carcinogenicity in humans and mice. Cancer Res (2012) 0.91
Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer. J Thorac Dis (2014) 0.91
Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Mol Cancer Ther (2009) 0.90
Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide. Br J Cancer (2012) 0.88
Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours. Br J Cancer (2008) 0.87
Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo. Neoplasia (2015) 0.87
KDR expression is associated with the stage and cigarette smoking of the patients with lung cancer. J Cancer Res Clin Oncol (2007) 0.86
Levels of circulating microparticles in lung cancer patients and possible prognostic value. Dis Markers (2013) 0.85
Human papillomavirus up-regulates MMP-2 and MMP-9 expression and activity by inducing interleukin-8 in lung adenocarcinomas. PLoS One (2013) 0.85
Circulating endothelial-derived activated microparticle: a useful biomarker for predicting one-year mortality in patients with advanced non-small cell lung cancer. Biomed Res Int (2014) 0.84
The -271 G>A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer. BMC Cancer (2009) 0.82
The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer. Ther Adv Med Oncol (2009) 0.81
URG4/URGCP enhances the angiogenic capacity of human hepatocellular carcinoma cells in vitro via activation of the NF-κB signaling pathway. BMC Cancer (2015) 0.81
Endothelial progenitor cells are associated with response to chemotherapy in human non-small-cell lung cancer. J Cancer Res Clin Oncol (2011) 0.81
Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab. Biologics (2007) 0.80
Activating transcription factor 3 is overexpressed in human glioma and its knockdown in glioblastoma cells causes growth inhibition both in vitro and in vivo. Int J Mol Med (2015) 0.78
Biomarkers and the genetics of early neoplastic lesions. Cancer Biomark (2010) 0.78
Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer. Int J Clin Oncol (2006) 0.78
Perceived health in lung cancer patients: the role of positive and negative affect. Qual Life Res (2011) 0.78
The efficacy and safety of thalidomide-based therapy in patients with advanced non-small cell lung cancer: a meta-analysis. Contemp Oncol (Pozn) (2014) 0.75
Single nucleotide polymorphisms of MAGE-A3 gene and its clinical implications in Chinese patients with non-small cell lung cancer (NSCLC). Chin J Cancer Res (2015) 0.75
Perfusion parameters as potential imaging biomarkers for the early prediction of radiotherapy response in a rat tumor model. Diagn Interv Radiol (2016) 0.75
A human IgG-like bispecific antibody co-targeting epidermal growth factor receptor and the vascular endothelial growth factor receptor 2 for enhanced antitumor activity. Cancer Biol Ther (2015) 0.75
Anti-vascular endothelial growth factor therapies at the crossroads: linifanib for non-small cell lung cancer. Transl Lung Cancer Res (2016) 0.75
Anti-angiogenic agents in the treatment of non-small cell lung cancer. Kardiochir Torakochirurgia Pol (2014) 0.75
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med (2002) 24.87
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2005) 7.55
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol (2006) 3.71
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol (2007) 2.93
Development of clinical trials in a cooperative group setting: the eastern cooperative oncology group. Clin Cancer Res (2008) 2.89
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res (2007) 2.52
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol (2006) 2.35
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res (2013) 1.90
Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol (2004) 1.84
Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol (2009) 1.64
Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol (2004) 1.53
Asthma in adventure travelers: a prospective study evaluating the occurrence and risk factors for acute exacerbations. Arch Intern Med (2002) 1.45
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther (2007) 1.32
Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol (2008) 1.29
Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs (2007) 1.24
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer (2009) 1.24
Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clin Cancer Res (2005) 1.23
Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. Int J Radiat Oncol Biol Phys (2007) 1.13
Smoking cessation after diagnosis of lung cancer is associated with a beneficial effect on performance status. Chest (2006) 1.11
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res (2008) 1.10
Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J Thorac Oncol (2009) 1.10
Weight loss and improvement of obesity-related illness in 500 U.S. patients following laparoscopic adjustable gastric banding procedure. Am J Surg (2005) 1.05
Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin Cancer Res (2005) 1.05
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer. J Clin Oncol (2003) 1.03
Use of an indwelling pleural catheter for the management of recurrent chylothorax in patients with cancer. Chest (2007) 1.01
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res (2007) 1.01
Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. Mol Cancer Ther (2006) 1.01
Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. J Clin Oncol (2003) 1.01
Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer Res (2006) 1.00
Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. Mol Cancer Ther (2007) 1.00
Current management of advanced non-small cell lung cancer: targeted therapy. Semin Oncol (2005) 1.00
A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin Cancer Res (2004) 1.00
Clinical utility of EUS-guided fine-needle aspiration of mediastinal masses in the absence of known pulmonary malignancy. Gastrointest Endosc (2002) 0.98
Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. Mol Cancer Ther (2002) 0.98
A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer (2002) 0.97
A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study. Biomarkers (2013) 0.96
Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res (2009) 0.95
Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC. Oncologist (2008) 0.94
A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979). Cancer Chemother Pharmacol (2003) 0.92
Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer. Cancer Epidemiol Biomarkers Prev (2007) 0.91
Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J Invest Dermatol (2004) 0.91
Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin Cancer Res (2009) 0.91
BAC consensus conference, November 4-6, 2004: epidemiology, pathogenesis, and preclinical models. J Thorac Oncol (2006) 0.90
Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemother Pharmacol (2009) 0.89
Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis. J Thorac Oncol (2012) 0.89
Identifying barriers associated with enrollment of patients with lung cancer into clinical trials. Clin Lung Cancer (2012) 0.85
Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors. Clin Lung Cancer (2011) 0.83
Establishing and sustaining a biorepository network in Israel: challenges and progress. Biopreserv Biobank (2013) 0.83
Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer. J Thorac Oncol (2013) 0.83
A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol (2013) 0.82
Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer. Clin Cancer Res (2006) 0.82
A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group. J Thorac Oncol (2009) 0.81
Targeted drug delivery strategies to treat lung metastasis. Expert Opin Drug Deliv (2009) 0.80
Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly. Cancer (2004) 0.79
Angiogenesis inhibition in the treatment of lung cancer. Clin Adv Hematol Oncol (2006) 0.79
Combined anti-proliferative and anti-angiogenic strategies for cancer. Expert Opin Pharmacother (2008) 0.78
Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. J Clin Oncol (2006) 0.78
Chromosomal numerical aberrations in apparently normal oral mucosa of heavy smokers affected by lung cancer. Oral Oncol (2009) 0.78
A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer. Clin Lung Cancer (2011) 0.78
Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study. Lung Cancer (2002) 0.78
Pulmonary manifestations in patients with cutaneous T-cell lymphomas. Cancer (2007) 0.77
The role of growth factor signaling in malignancy. Cancer Treat Res (2003) 0.77
Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC. A Hoosier Oncology Group (HOG) phase II study. Lung Cancer (2002) 0.77
Multitargeted inhibitors in lung cancer: new clinical data. Clin Lung Cancer (2008) 0.77
Ongoing and future trials of biologic therapies in lung cancer. Lung Cancer (2003) 0.77
Pulmonary dysfunction as a major cause of inoperability among patients with non-small-cell lung cancer. Clin Lung Cancer (2006) 0.77
A better crystal ball to predict lung-cancer survival? Lancet Oncol (2006) 0.76
Structural basis for hyperpermeability of tumor vessels in advanced lung adenocarcinoma complicated by pleural effusion. Clin Lung Cancer (2013) 0.76
Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. J Thorac Oncol (2014) 0.76
An advance in small-cell lung cancer treatment--more or less. J Natl Cancer Inst (2003) 0.75
Angiogenesis and lung cancer: implications for prognosis and treatment. Lancet Oncol (2007) 0.75
Anti-angiogenic treatments in advanced NSCLC: back to the drawing board. J Thorac Dis (2012) 0.75
Induced sputum for identifying sarcoidosis in patients with uveitis. Ophthalmology (2002) 0.75
Lung cancer adjuvant therapy. Cancer J (2007) 0.75
EGFR mutation testing practice in advanced non-small cell lung cancer. Lung (2014) 0.75
New targets for the treatment of advanced non-small cell lung cancer. Cancer Chemother Biol Response Modif (2002) 0.75
Lung cancer in the elderly: current and future chemotherapeutic options. Drugs Aging (2002) 0.75
Systemic issues in small cell lung cancer. Curr Probl Cancer (2012) 0.75
Karnofsky performance score as a predictor of survival in soft tissue sarcoma. Clin Orthop Relat Res (2002) 0.75
[Tissue repositories for research at Sheba Medical Center(SMC]. Harefuah (2013) 0.75
Radiotherapy improves survival in unresected stage I-III bronchoalveolar carcinoma. Int J Radiat Oncol Biol Phys (2012) 0.75
Chemotherapy and antiangiogenic agents in non-small-cell lung cancer. Clin Lung Cancer (2007) 0.75